5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

 

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology
Avatar

Non-Muscle Invasive Bladder Cancer, Pembro Approval and New agents Oportuzumab Monatox and Nadofaragene Firadenovec

By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Brad Somer
By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Brad Somer
177 views
March 13, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Genitourinary Cancers
23:02
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Current Landscape of Molecular Testing in Prostate Cancer: Which Tes…

Feat. D. Vaena
07:04
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Non-Muscle Invasive Bladder Cancer, Pembro Approval and New agents O…

Feat. B. Somer
14:55
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Management of Metastatic Urothelial Cancer: Prognostic Value of ctDN…

Feat. B. Somer
08:49
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Case Study Presentation on Treatment Approach for mUC: What Are the …

Feat. H. Greene
09:31
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Erdafitinib Treatment of 77 y/o Female With Metastatic Urothelial Ca…

Feat. H. Greene